TY - JOUR
T1 - When targeted therapy for cancer leads to ICU admission. RETRO-TARGETICU multicentric study
AU - Meert, Anne Pascale
AU - Toffart, Anne Claire
AU - Picard, Muriel
AU - Jaubert, Paul
AU - Gibelin, Aude
AU - Bauer, Philippe
AU - Mokart, Djamel
AU - Van De Louw, Andry
AU - Hatzl, Stefan
AU - Moreno-Gonzales, Gabriel
AU - Rousseau-Bussac, Gaelle
AU - Bruneel, Fabrice
AU - Montini, Luca
AU - Moreau, Anne Sophie
AU - Carpentier, Dorothée
AU - Seguin, Amelie
AU - Hemelaar, Pleun
AU - Azoulay, Elie
AU - Lemiale, Virginie
N1 - Publisher Copyright:
© 2022 Société Française du Cancer
PY - 2022/9
Y1 - 2022/9
N2 - Purpose: To study prevalence of targeted therapy (TT)-related adverse events requiring ICU admission in solid tumor patients. Methods: Retrospective multicenter study from the Nine-i research group. Adult patients who received TT for solid tumor within 3 months prior to ICU admission were included. Patients admitted for TT-related adverse event were compared to those admitted for other reasons. Results: In total, 140 patients, median age of 63 (52–69) years were included. Primary cancer site was mostly digestive (n = 27, 19%), kidney (n = 27, 19%), breast (n = 24, 17%), and lung (n = 20, 14%). Targeted therapy was anti-VEGF/VEGFR for 27% (n = 38) patients, anti-EGFR for 22% (n = 31) patients, anti-HER2 for 14% (n = 20) patients and anti-BRAF for 9% (n = 5) patients. ICU admission was related to TT adverse events for 30 (21%) patients. The most frequent complications were interstitial pneumonia (n = 7), cardiac failure (n = 5), anaphylaxis (n = 4) and bleeding (n = 4). At ICU admission, no significant difference was found between patients admitted for a TT-related adverse event and the other patients. One-month survival rate was higher in patients admitted for TT adverse event (OR = 5.733 [2.031–16.182] P < 0.001). Conclusions: Adverse events related to targeted therapy accounted for 20% of ICU admission in our population and carried a 16% one-month mortality. Outcome was associated with admission for TT related to adverse event, breast cancer and good performance status.
AB - Purpose: To study prevalence of targeted therapy (TT)-related adverse events requiring ICU admission in solid tumor patients. Methods: Retrospective multicenter study from the Nine-i research group. Adult patients who received TT for solid tumor within 3 months prior to ICU admission were included. Patients admitted for TT-related adverse event were compared to those admitted for other reasons. Results: In total, 140 patients, median age of 63 (52–69) years were included. Primary cancer site was mostly digestive (n = 27, 19%), kidney (n = 27, 19%), breast (n = 24, 17%), and lung (n = 20, 14%). Targeted therapy was anti-VEGF/VEGFR for 27% (n = 38) patients, anti-EGFR for 22% (n = 31) patients, anti-HER2 for 14% (n = 20) patients and anti-BRAF for 9% (n = 5) patients. ICU admission was related to TT adverse events for 30 (21%) patients. The most frequent complications were interstitial pneumonia (n = 7), cardiac failure (n = 5), anaphylaxis (n = 4) and bleeding (n = 4). At ICU admission, no significant difference was found between patients admitted for a TT-related adverse event and the other patients. One-month survival rate was higher in patients admitted for TT adverse event (OR = 5.733 [2.031–16.182] P < 0.001). Conclusions: Adverse events related to targeted therapy accounted for 20% of ICU admission in our population and carried a 16% one-month mortality. Outcome was associated with admission for TT related to adverse event, breast cancer and good performance status.
UR - http://www.scopus.com/inward/record.url?scp=85132723750&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85132723750&partnerID=8YFLogxK
U2 - 10.1016/j.bulcan.2022.04.014
DO - 10.1016/j.bulcan.2022.04.014
M3 - Article
C2 - 35718570
AN - SCOPUS:85132723750
SN - 0007-4551
VL - 109
SP - 916
EP - 924
JO - Bulletin du Cancer
JF - Bulletin du Cancer
IS - 9
ER -